Fredericks Michael & Co. acted as exclusive financial advisor to WerfenLife SA, a leading in vitro diagnostic solutions developer, manufacturer and distributor of highly specialized products for Healthcare and Life Sciences, on its acquisition of CA Casyso AG together with its Tem® subsidiaries. The consideration was EUR 125mn. Casysos’s Tem® subsidiaries specialize in the development, production and distribution of viscoelastic diagnostic testing through its Rotem® systems, which help make better decisions about the need of blood transfusion and use of blood products (Patient Blood Management (“PBM”)). This technology improves patient outcomes while reducing hospital costs. WerfenLife, headquartered in Barcelona (Spain), acquired Casyso, headquartered in Basel (Switzerland) through its subsidiary Instrumentation Laboratory Inc. (“IL”) headquartered in Bedford (MA, United States). The acquisition enables WerfenLife to expand their leadership in Hemostasis and Critical Care in vitro diagnostic.
“A passion for innovation, leading systems and extensive knowledge in PBM, make Tem® a perfect complement to our focus, commitment, and leadership in Hemostasis and Critical Care IVD,” said Ramon Benet, CEO at IL. “IL and our global Werfen organizations are ideally positioned to maximize the potential of the Rotem® testing systems, which intersect our existing business and present synergies in our core competencies and customer call points. Most importantly, Rotem® systems share the same ultimate benefit of all our products ─ to help customers reduce overall hospital costs, while improving patient care.”
The acquisition reflects WerfenLife’s strategy of growth through the acquisition of high-quality companies, with complementary expertise and access to new markets. At the same time, Tem® will be able to widen the range of services offered to its clients and expand into areas where WerfenLife is already strong as an in vitro diagnostic solutions developer.
FM&Co.’s advisory services to WerfenLife included contacting and meeting with Casyso, valuing, structuring, and negotiating the terms and conditions of the agreement.
About WerfenLife SA
WerfenLife is a global company, with a direct presence in 30 countries and a distribution network spanning more than 80 countries worldwide. WerfenLife is a global leader in the fields of Hemostasis, Critical Care and Autoimmunity diagnostics. Its product portfolios encompass instruments, software, reagents and service. WerfenLife serves hospitals and clinical laboratories worldwide. WerfenLife was founded in 1966 with manufacturing facilities in the United States, Spain, and Italy. For more information, visit www.werfenlife.com
About Instrumentation Laboratory Inc.
Instrumentation Laboratory Inc. is the leading manufacturer of instruments and reagents for the Hemostasis market worldwide. IL has continually been at the forefront of innovation in Hemostasis testing, culminating in the new ACL TOP Family 50 Series Hemostasis Testing Systems with automated pre-analytical sample checks. The ACL TOP Family of fully automated analyzers is the number one Hemostasis analyzer platform in the world. Coupled with a comprehensive menu of HemosIL® reagents and a full complement of supporting services, software, and automation solutions, IL offers complete Disease State Management in Hemostasis. For more information, visit www.instrumentationlaboratory.com
About the Tem Group
The Tem Group is an international medical technology company. The Tem Group includes two companies in Munich, development and production sites in the USA and in UK and several sales offices worldwide. Tem Innovations GmbH deals with the development and production of Rotem® point-of-care diagnostic equipment and reagents. Tem International GmbH handles the sales distribution, marketing and customer service. The global activities of both companies are coordinated from the global headquarters in Basel. Since its founding in 2000, the group now employs about 130 people worldwide. For more information, visit www.rotem.de/en
